These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
513 related articles for article (PubMed ID: 9753033)
1. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Bladé J; Samson D; Reece D; Apperley J; Björkstrand B; Gahrton G; Gertz M; Giralt S; Jagannath S; Vesole D Br J Haematol; 1998 Sep; 102(5):1115-23. PubMed ID: 9753033 [No Abstract] [Full Text] [Related]
2. Salvage use of allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning from unrelated donors in multiple myeloma. A study by the Plasma Cell Disorders subcommittee of the European Group for Blood and Marrow Transplant Chronic Malignancies Working Party. Sobh M; Michallet M; Dubois V; Iacobelli S; Koster L; Van Biezen A; Fegueux N; Tabrizi R; Finke J; El-Cheikh J; Schipperus M; Meijer E; von dem Borne P; Petersen E; Russell N; Tholouli E; Passweg J; Garban F; Maertens J; Chevalier P; Maillard N; Volin L; Francois S; Lioure B; Beguin Y; Gluckman E; Ruggeri A; Garderet L; Kröger N Haematologica; 2017 Jul; 102(7):e271-e274. PubMed ID: 28428268 [No Abstract] [Full Text] [Related]
3. The role of high-dose chemotherapy in the treatment of multiple myeloma: a controversy. Kyle RA Ann Oncol; 2000; 11 Suppl 1():55-8. PubMed ID: 10707780 [TBL] [Abstract][Full Text] [Related]
4. High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma. Kumar L; Raju GM; Ganessan K; Shawgi S; Menon H; Wadhwa J; Sharma A; Singh R; Kochupillai V Natl Med J India; 2003; 16(1):16-21. PubMed ID: 12715951 [TBL] [Abstract][Full Text] [Related]
5. Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting). Bruno B; Auner HW; Gahrton G; Garderet L; Festuccia M; Ladetto M; Lemoli RM; Massaia M; Morris C; Palumbo A; Schönland S; Boccadoro M; Kröger N Leuk Lymphoma; 2016; 57(6):1256-68. PubMed ID: 26735310 [TBL] [Abstract][Full Text] [Related]
6. Role of hematopoietic stem cell transplantation in multiple myeloma. Garcia IN Clin Lymphoma Myeloma Leuk; 2015 Feb; 15(2):86-91. PubMed ID: 25131852 [TBL] [Abstract][Full Text] [Related]
7. Autologous stem-cell transplantation in multiple myeloma. Gahrton G Wien Med Wochenschr; 1995; 145(2-3):52-4. PubMed ID: 7762254 [TBL] [Abstract][Full Text] [Related]
8. Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma. Gertz MA; Lacy MQ; Inwards DJ; Chen MG; Pineda AA; Gastineau DA; Greipp PR; Lust JA; Tefferi A; Witzig TE; Kyle RA; Litzow MR Bone Marrow Transplant; 1999 Feb; 23(3):221-6. PubMed ID: 10084252 [TBL] [Abstract][Full Text] [Related]
9. The role of tandem stem cell transplantation for multiple myeloma patients. Martino M; Recchia AG; Fedele R; Neri S; Vincelli ID; Moscato T; Gentile M; Morabito F Expert Opin Biol Ther; 2016; 16(4):515-34. PubMed ID: 26698133 [TBL] [Abstract][Full Text] [Related]
10. Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT). Björkstrand B; Svensson H; Goldschmidt H; Ljungman P; Apperley J; Mandelli F; Marcus R; Boogaerts M; Alegre A; Remes K; Cornelissen JJ; Bladé J; Lenhoff S; Iriondo A; Carlson K; Volin L; Littlewood T; Goldstone AH; San Miguel J; Schattenberg A; Gahrton G Bone Marrow Transplant; 2001 Mar; 27(5):511-5. PubMed ID: 11313685 [TBL] [Abstract][Full Text] [Related]
11. [Maintenance treatment with interferon-alfa in multiple myeloma after autotransplantation of peripheral blood progenitor cells. Spanish Register of Transplantation in Myeloma]. García Laraña J; Díaz Mediavilla J; Martínez R; Lahuerta JJ; Alegre A; Odriozola J; Sureda A; San Miguel J; De la Rubia J; Escudero A; Conde E; Bladé J; Cabrera R; Gastearena J; Besalduch J; Vidal MJ; Hernández F; Rifon J; Leon A; Mataix R; Parody R; Moraleda JM; Solano C; de Pablos JM; Sánchez JJ Sangre (Barc); 1997 Apr; 42 Suppl 1():38-41. PubMed ID: 9381300 [No Abstract] [Full Text] [Related]
12. Update on the treatment of multiple myeloma. Kyle RA Oncologist; 2001; 6(2):119-24. PubMed ID: 11306723 [TBL] [Abstract][Full Text] [Related]
14. Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib. Aypar E; İzzettin FV; Akı ŞZ; Sancar M; Yeğin ZA; Türköz-Sucak G J Oncol Pharm Pract; 2018 Jun; 24(4):281-289. PubMed ID: 29284356 [TBL] [Abstract][Full Text] [Related]
15. Allogeneic hematopoietic stem cell transplantation for multiple myeloma: curative but not the standard of care. Koehne G; Giralt S Curr Opin Oncol; 2012 Nov; 24(6):720-6. PubMed ID: 22960558 [TBL] [Abstract][Full Text] [Related]